CHL Medical Partners

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

CareWell Urgent Care operates emergency health care centers in the New England area. Its approach to urgent care includes on-site labs, x-ray capabilities, and dispensing of common medications. CareWell Urgent Care is based in Tewksbury, Massachusetts.

Ambra Health is a medical data and image management software-as-a-service company that provides a cloud-based platform for healthcare providers. The platform is designed to enhance imaging innovation and improve collaborative care workflows by offering secure and easy access to medical images. It serves a diverse clientele, including major health systems and radiology practices, enabling them to streamline their operations and enhance patient care. Ambra Health's solutions focus on agility, interoperability, and user-friendly design, allowing organizations to adopt and integrate the technology effectively while improving business outcomes. The company aims to meet the evolving needs of the healthcare industry by delivering innovative medical image management solutions.

OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, that specializes in developing molecular diagnostics and informatics aimed at combating infectious diseases. The company offers a range of products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and antimicrobial resistance markers, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to help manage multidrug-resistant organisms in healthcare settings. Through its strategic collaboration with the New York State Department of Health, OpGen is working on solutions to detect and manage antimicrobial-resistant infections in healthcare facilities. The company's innovative technologies are utilized by academic, government, and research institutions globally for applications such as strain typing and genome assembly. OpGen aims to enhance patient care and outcomes while addressing the growing challenge of antibiotic resistance.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Ambra Health is a medical data and image management software-as-a-service company that provides a cloud-based platform for healthcare providers. The platform is designed to enhance imaging innovation and improve collaborative care workflows by offering secure and easy access to medical images. It serves a diverse clientele, including major health systems and radiology practices, enabling them to streamline their operations and enhance patient care. Ambra Health's solutions focus on agility, interoperability, and user-friendly design, allowing organizations to adopt and integrate the technology effectively while improving business outcomes. The company aims to meet the evolving needs of the healthcare industry by delivering innovative medical image management solutions.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.

OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, that specializes in developing molecular diagnostics and informatics aimed at combating infectious diseases. The company offers a range of products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and antimicrobial resistance markers, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to help manage multidrug-resistant organisms in healthcare settings. Through its strategic collaboration with the New York State Department of Health, OpGen is working on solutions to detect and manage antimicrobial-resistant infections in healthcare facilities. The company's innovative technologies are utilized by academic, government, and research institutions globally for applications such as strain typing and genome assembly. OpGen aims to enhance patient care and outcomes while addressing the growing challenge of antibiotic resistance.

Vertos Medical Inc. is a medical device company based in Aliso Viejo, California, founded in 2005 by Dr. Dave Solsberg and Dr. Don Schomer. The company specializes in developing minimally invasive treatments for lumbar spinal stenosis (LSS), a common spinal condition. Its flagship product, the mild device, facilitates an outpatient treatment that is fluoroscopically guided and does not require the use of implants. This device includes components such as tissue sculptors, portals, trocars, and surgical clamps, allowing physicians to perform lumbar decompression procedures with local anesthesia. By restoring space in the spinal canal and alleviating pressure on the nerves, Vertos Medical's solutions aim to improve patient mobility and quality of life. The company's devices are primarily offered in the United States.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

Vertos Medical Inc. is a medical device company based in Aliso Viejo, California, founded in 2005 by Dr. Dave Solsberg and Dr. Don Schomer. The company specializes in developing minimally invasive treatments for lumbar spinal stenosis (LSS), a common spinal condition. Its flagship product, the mild device, facilitates an outpatient treatment that is fluoroscopically guided and does not require the use of implants. This device includes components such as tissue sculptors, portals, trocars, and surgical clamps, allowing physicians to perform lumbar decompression procedures with local anesthesia. By restoring space in the spinal canal and alleviating pressure on the nerves, Vertos Medical's solutions aim to improve patient mobility and quality of life. The company's devices are primarily offered in the United States.

North American Scientific is engaged in the design, development, manufacture, and sale of radioisotopic products for the treatment of cancer. The company offers Prospera I-125, an iodine-based seed and Prospera Pd-103, a palladium-based seed for the treatment of prostate cancer; SurTRAK needles and strands used primarily for the treatment of prostate cancer; and STP-110 Precision Stepper and RTP-6000 Precision Stabilizer equipment, which positions and holds the trans-rectal ultrasound probe during the LDR brachytherapy procedure as well as radiation shielding and needle loading accessories such as horizontal needle box; and needle-loading shield, box, and carousel. The company also offers ClearPath, a multi-catheter breast brachytherapy device for accelerated partial breast irradiation treatment for women with early-stage breast cancer. North American Scientific was founded in 1987 and is based in Chatsworth, California, United States.

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

Bikam Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. Bikam's primary innovation lies in its small molecule, non-retinoid pharmacological chaperones, which target misfolded proteins within the retina. These pharmacological chaperones are designed to bind to misfolded rod opsin, a protein associated with retinitis pigmentosa, facilitating its proper trafficking to rod cell surfaces and outer segments. Through its research and development efforts, Bikam Pharmaceuticals aims to address critical unmet medical needs in the field of ophthalmology, particularly for rare genetic disorders that can lead to blindness.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, that specializes in developing molecular diagnostics and informatics aimed at combating infectious diseases. The company offers a range of products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and antimicrobial resistance markers, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to help manage multidrug-resistant organisms in healthcare settings. Through its strategic collaboration with the New York State Department of Health, OpGen is working on solutions to detect and manage antimicrobial-resistant infections in healthcare facilities. The company's innovative technologies are utilized by academic, government, and research institutions globally for applications such as strain typing and genome assembly. OpGen aims to enhance patient care and outcomes while addressing the growing challenge of antibiotic resistance.

Millennium Pharmacy Systems is a pharmacy services provider to the long-term care industry. Offering a new approach to pharmacy services, Millennium delivers on the promise of "the right drug, for the right patient, at the right time, for the right price" so its customers can deliver the best patient care while reducing costs, and more easily meeting compliance demands. Only Millennium combines Just-In-Time Dispensing with electronic medication and treatment ordering, administration, documentation, and reporting. Millennium backs up the commitment with delivery timeliness and medication accuracy customer guarantees. Millennium is headquartered in Chicago, Illinois.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Ascend Health Corporation is a behavioral healthcare provider, offering a full range of inpatient and day hospital services to children, adolescents, adults and seniors. They focus on personal choice and specialized care. Their facilities provide high quality care by working closely to integrate their services with the healthcare system in each local community.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Cantex Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative cancer treatments. The company specializes in repurposing established therapies to create safer and more effective options for patients. Its lead product, ODSH, is a modified low anticoagulant heparin derivative designed to mitigate the adverse effects of chemotherapy on platelet counts. Additionally, Cantex offers Disulfiram-Copper Chelate, which targets multiple mechanisms to eliminate cancer stem cells, particularly for metastatic breast cancer, pancreatic cancer, and glioblastoma. By addressing significant unmet medical needs, Cantex Pharmaceuticals aims to provide high-value therapeutic solutions in the oncology market. Founded in 2002 and based in Weston, Florida, the company was previously known as PARINGENIX INC.

Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Oculir develops non-invasive glucose meter that measures glucose from the conjunctiva of the eye.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

GeneOhm Sciences designs, develops, and delivers nucleic acid-based diagnostic solutions. It focuses on serving the unmet diagnostic needs in a wide range of diseases including inherited disease, infectious disease and oncology. It is developing rapid, nucleic acid-based systems that will detect and identify infectious agents and genetic variations. GeneOhm Sciences is dedicated to offering laboratories and clinical scientists cutting-edge, FDA-approved, molecular based tests that can provide results in less than two hours. Established in San Diego, California in 2001, GeneOhm Sciences merged with Infectio Diagnostic, Inc. of Québec, Canada in 2004. The integrated company combines an extensive portfolio of proprietary technology, strong industry expertise and capabilities with an experienced and accomplished management team to lead the way. Most of GeneOhm’s development focus is on the applications electric current flowing through DNA as a means to detect genetic mutations. GeneOhm was recently acquired by the BD Pharmaceuticals group.

GeneOhm Sciences designs, develops, and delivers nucleic acid-based diagnostic solutions. It focuses on serving the unmet diagnostic needs in a wide range of diseases including inherited disease, infectious disease and oncology. It is developing rapid, nucleic acid-based systems that will detect and identify infectious agents and genetic variations. GeneOhm Sciences is dedicated to offering laboratories and clinical scientists cutting-edge, FDA-approved, molecular based tests that can provide results in less than two hours. Established in San Diego, California in 2001, GeneOhm Sciences merged with Infectio Diagnostic, Inc. of Québec, Canada in 2004. The integrated company combines an extensive portfolio of proprietary technology, strong industry expertise and capabilities with an experienced and accomplished management team to lead the way. Most of GeneOhm’s development focus is on the applications electric current flowing through DNA as a means to detect genetic mutations. GeneOhm was recently acquired by the BD Pharmaceuticals group.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

RxCentric is an e-health company that specializes in providing online marketing solutions for pharmaceutical companies. It connects physicians with essential drug information and educational resources through a targeted digital platform. By offering rapid access to comprehensive and reliable drug information, RxCentric aims to enhance the educational needs of healthcare professionals and improve their decision-making processes regarding pharmaceutical products.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

RxCentric is an e-health company that specializes in providing online marketing solutions for pharmaceutical companies. It connects physicians with essential drug information and educational resources through a targeted digital platform. By offering rapid access to comprehensive and reliable drug information, RxCentric aims to enhance the educational needs of healthcare professionals and improve their decision-making processes regarding pharmaceutical products.

Protometrix develops integrated proteomics technologies to improve human health. Protometrix focuses on the production and investigation of the function and interaction of proteins in parallel using nanoscale technology and collection of information in an informatics database.

Molecular Staging, Inc., a life sciences tool company, develops technologies for the detection and measurement of proteins and nucleic acids. It provides technologies for proteomics, genomics, pharmacogenomics, and diagnostics applications. The company’s products and services include protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins; whole-genome amplification that allows DNA samples as resources, enabling researchers to return to them for new tests or confirmatory diagnoses; and multiplexed diagnostics that enable earlier detection of disease.

Lifespire was created in late 1999 through the merging of 2 companies: Vida Healthcare and inspiria.com. Vida Healthcare, formed in 1996, has worked with hundreds of oncology doctors, nurses and allied health professionals to improve cancer care. Lifespire Their vision is to improve care through shared knowledge. But what does that mean to you, the patient, and your circle of family and friends They serve? It means that They are giving you and the ones closest to you -- your circle of care -- a resource for gathering credible knowledge, support and understanding of your experience with cancer. Some of you may have known us when They were Vida Healthcare. In Their four years as Vida, They delivered clinical support and education services to over 4,000 people experiencing cancer. Now They're bringing that experience and understanding to you. They're doing this in partnership with companies committed to improving the treatment of cancer. And They're using Lifespire.com as Their forum for delivery.

RxCentric is an e-health company that specializes in providing online marketing solutions for pharmaceutical companies. It connects physicians with essential drug information and educational resources through a targeted digital platform. By offering rapid access to comprehensive and reliable drug information, RxCentric aims to enhance the educational needs of healthcare professionals and improve their decision-making processes regarding pharmaceutical products.

ICOS Corporation is a biotechnology company that engages in the discovery, development, and commercialization of therapeutic products. It is engaged in the commercialization of treatments for unmet medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. It is the developer of a treatment known as Cialis (tadalafil), a product for the treatment of erectile dysfunction through its joint venture with Eli Lilly and Company in North America and Europe. It is also engaged in contract manufacturing services for third parties. It is in a strategic alliance with Solvay Pharmaceuticals, Inc. ICOS Corporation was established in 1989, based in Bothell, Washington. It is currently operated by Eli Lilly and Company.